A case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy
Abstract Neuregulin 1 (NRG1) gene fusion is a rare oncogenic driver gene in multiple tumor types, leading to the activation of the epidermal growth factor receptor (ErbB)‐mediated pathway. Therefore, afatinib, a pan‐ErbB family inhibitor, may be a therapeutic candidate for NRG1 fusion‐driven tumors....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14636 |